Current advances in treatment of gastroparesis

Bibliography

• Camilleri M, Parkman HP, Shafi MA, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108(1):18-37
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M. Prokinetics in Gastroparesis. Gastroenterol Clin North Am 2015;44(1):97-111
   PubMed Web of Science ®Google Scholar
• McCallum RW, Sunny JJr. Status of pharmacologic management of gastroparesis: 2014. Pract Gastroenterol 2014;38:9
   Google Scholar
• Perkel MS, Moore C, Hersh T, et al. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci 1979;24(9):662-6
   PubMed Web of Science ®Google Scholar
• Perkel MS, Hersh T, Moore C, et al. Metoclopramide therapy in fifty-five patients with delayed gastric emptying. Am J Gastroenterol 1980;74(3):231-6
   PubMed Web of Science ®Google Scholar
• McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6(5):463-7
   PubMed Web of Science ®Google Scholar
• Ricci DA, Saltzman MB, Meyer C, et al. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 1985;7(1):25-32
   PubMed Web of Science ®Google Scholar
• Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94(5):1230-4
   PubMed Web of Science ®Google Scholar
• Erbas T, Varoglu E, Erbas B, et al. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16(11):1511-14
   PubMed Web of Science ®Google Scholar
• Malagelada JR, Rees WD, Mazzotta LJ, et al. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology 1980;78(2):286-93
   PubMed Web of Science ®Google Scholar
• Snape WJJr, Battle WM, Schwartz SS, et al. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann Intern Med 1982;96(4):444-6
   PubMed Web of Science ®Google Scholar
• Valenzuela JE, Dooley CP. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol Suppl 1984;96:127-36
   PubMedGoogle Scholar
• Berkowitz DM, McCallum RW. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980;27(3):414-20
   PubMed Web of Science ®Google Scholar
• Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab 2010;5(5):653-62
   PubMedGoogle Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11-19
   PubMed Web of Science ®Google Scholar
• Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19(4):379-90
   PubMed Web of Science ®Google Scholar
• Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102(9):2036-45
   PubMed Web of Science ®Google Scholar
• Watts GF, Armitage M, Sinclair J, et al. Treatment of diabetic gastroparesis with oral domperidone. Diabet Med 1985;2(6):491-2
   PubMed Web of Science ®Google Scholar
• Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord 1997;12(6):952-7
   PubMed Web of Science ®Google Scholar
• Kozarek R. Domperidone for symptomatic management of diabetic gastroparesis in metoclopramide treatment failures. Adv Ther 1990;7:61-8
   Google Scholar
• Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 1989;84(9):1069-75
   PubMed Web of Science ®Google Scholar
• Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30(1):1-9
   PubMed Web of Science ®Google Scholar
• Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group. Clin Ther 1998;20(3):438-53
   PubMed Web of Science ®Google Scholar
• Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990;322(15):1028-31
   PubMed Web of Science ®Google Scholar
• Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992;33(3):397-401
   PubMed Web of Science ®Google Scholar
• Parkman HP, Pagano AP, Vozzelli MA, et al. Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. Am J Phys 1995;269(3 Pt 1):G418-26
   PubMed Web of Science ®Google Scholar
• Weber FHJr, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993;88(4):485-90
   PubMed Web of Science ®Google Scholar
• Sturm A, Holtmann G, Goebell H, et al. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999;60(5):422-7
   PubMed Web of Science ®Google Scholar
• Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88(2):203-7
   PubMed Web of Science ®Google Scholar
• Larson JM, Tavakkoli A, Drane WE, et al. Advantages of azithromycin over erythromycin in improving gastric empyting half-time in adult patients with gastroparesis. J Neurogastroenterol Motil 2010;16(4):407-13
   PubMedGoogle Scholar
• Leming S, Broad J, Cozens SJ, et al. GSK962040: a small molecule motilin receptoragonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil 2011;23(10):958-958e410
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009;21(6):657-64
   PubMed Web of Science ®Google Scholar
• Depoortere I. Can small non-peptide motilin agonists force a breakthrough as gastroprokinetic drugs? Br J of Pharmacol 2012;167:760-2
   PubMed Web of Science ®Google Scholar
• Barshop K, Kuo B. The investigational drug camicanal for the treatment of gastroparesis. Expert Opin. Investig. Drugs 2015;24(1):133-40
   Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes AJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterology Motility 2008;20:99-112
   PubMed Web of Science ®Google Scholar
• Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists:potential for treatment of gastrointestinal motility disorders. Expert Opin InvestigDrugs 2010;19(6):765-75
   PubMed Web of Science ®Google Scholar
• Shin A, Acosta A, Camilleri M, et al. A randomized trial of 5-Hydroxytryptamine 4-receptor agonist, YKP10811, on colonic transit and bowel function in functionalconstipation. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21(12):1256-e117
   PubMed Web of Science ®Google Scholar
• Bouras E, Camilleri M, Burton D, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120(2):354-60
   PubMed Web of Science ®Google Scholar
• Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22(1):42-9
   PubMed Web of Science ®Google Scholar
• Bortolotti M, Cucchiara S, Sarti P, et al. Comparison between the effects of neostigmine and ranitidine on interdigestive gastroduodenal motility of patients with gastroparesis. Digestion 1995;56(2):96-9
   PubMed Web of Science ®Google Scholar
• Lucey MA, Patil V, Girling K, et al. Does neostigmine increase gastric emptying in the critically ill?–results of a pilot study. Crit Care Resusc 2003;5(1):14-19
   PubMedGoogle Scholar
• Pasha SF, Lunsford TN, Lennon VA. Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology 2006;131(5):1592-6
   PubMed Web of Science ®Google Scholar
• Nowlan ML, Scott LJ. Acotiamide: a first global approval. Drugs 2013;73(12):1377-83
   PubMed Web of Science ®Google Scholar
• Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009;6(6):343-52
   PubMed Web of Science ®Google Scholar
• Fukuda H, Mizuta Y, Isomoto H, et al. Ghrelin enhances gastric motility through direct stimulation of intrinsic neural pathways and capsaicin-sensitive afferent neurones in rats. Scand J Gastroenterol 2004;39(12):1209-14
   PubMed Web of Science ®Google Scholar
• Peeters TL. Central and peripheral mechanisms by which ghrelin regulates gut motility. J Physiol Pharmacol 2003;54(Suppl 4):95-103
   PubMedGoogle Scholar
• Trudel L, Tomasetto C, Rio MC, et al. Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002;282(6):G948-52
   PubMed Web of Science ®Google Scholar
• Dass NB, Munonyara M, Bassil AK, et al. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience 2003;120(2):443-53
   PubMed Web of Science ®Google Scholar
• Tack J, Depoortere I, Bisschops R, et al. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005;22(9):847-53
   PubMed Web of Science ®Google Scholar
• Murray CD, Martin NM, Patteson M, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005;54:1693-8
   PubMed Web of Science ®Google Scholar
• Binn M, Albert C, Gougeon A, et al. Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. Peptides 2006;27:1603-6
   PubMed Web of Science ®Google Scholar
• Levin F, Edholm T, Schmidt PT, et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab 2006;91:3296-302
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterology Motility 2010;22:1069-e281
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Vestergaard ET, Hellström PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009;29(11):1179-87
   PubMed Web of Science ®Google Scholar
• Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25(2):e140-50
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M, McCallum R, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014;146(Suppl 1):S158-9
   Google Scholar
• Camilleri M, Acosta A. Emerging treatments in Neurogastroenterology: remlamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Auteri M, Zizzo MG, Serio R. GABA and GABA receptor in the gastrointestinal tract: from motility to inflammatation. Pharmacol Res 2014;93:11-21
   PubMedGoogle Scholar
• Boeckxstaens GE. Reflux inhibitors: a new approach for GERD? Curr Opin Pharmacol 2008;8(6):685-9
   PubMed Web of Science ®Google Scholar
• Collares EF, Vinagre AM. Effect of baclofen on liquid and solid gastric emptying in rats. Arq Gastroenterol 2010;47(3):290-6
   PubMedGoogle Scholar
• Andrews PL, Wood KL. Systemic baclofen stimulates gastric motility and secretion via a central action in the rat. Br J Pharmacol 1986;89(3):461-7
   PubMed Web of Science ®Google Scholar
• Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006;149(4):468-74
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha A, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol 2011;9(1):5-e7
   PubMed Web of Science ®Google Scholar
• Owczuk R, Twardowski P, Dylczyk-Sommer A, et al. Influence of promethazine on cardiac repolarisation: a double-blind, midazolam-controlledstudy. Anaesthesia 2009;64:609-14
   PubMed Web of Science ®Google Scholar
• Barrett TW, DiPersio DM, Jenkins CA, et al. A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. Am J Emerg Med 2011;29:247-55
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Hvid-Jacobsen K, Lund P, et al. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990;46(2):89-96
   PubMed Web of Science ®Google Scholar
• Netzer P, Gaia C, Lourens ST, et al. Does intravenous ondansetron affect gastric emptying of a solid meal, gastric electrical activity or blood hormone levels in healthy volunteers? Aliment Pharmacol Ther 2002;16(1):119-27
   PubMed Web of Science ®Google Scholar
• Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011;19(10):1609-17
   PubMed Web of Science ®Google Scholar
• Simmons K, Parkman HP. Granisetron trandermal system improves refractory nausea and vomiting in gastroparesis. Dig Dis Sci 2014;59(6):1231-4
   PubMed Web of Science ®Google Scholar
• Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry 2002;63(Suppl 11):6-10
   PubMed Web of Science ®Google Scholar
• Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996;35(8):1121-9
   PubMed Web of Science ®Google Scholar
• Bountra C, Bunce K, Dale T, et al. Antiemetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993;249(1):R3-4
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21(22):4112-19
   PubMed Web of Science ®Google Scholar
• Uchida M, Ikesue H, Kato K, et al. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy. Am J Health Syst Pharm 2013;70(4):343-9
   PubMed Web of Science ®Google Scholar
• Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother 2012;46(12):e38
   PubMedGoogle Scholar
• Chong K, Dhatariya K. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. Nat Rev Endocrinol 2009;5(5):285-8
   PubMed Web of Science ®Google Scholar
• Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 2007;23(3):533-43
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Eckert D, et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil 2012;24:358-e169
   PubMed Web of Science ®Google Scholar
• Prakash C, Lustman PJ, Freedland KE, et al. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci 1998;43:1951-6
   PubMed Web of Science ®Google Scholar
• Sawhney MS, Prakash C, Lustman PJ, et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci 2007;52:418-24
   PubMed Web of Science ®Google Scholar
• Kumar A, Attaluri A, Hashmi S, et al. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 2008;20:635-42
   PubMed Web of Science ®Google Scholar
• Samsom M, Salet GA, Roelofs JM, et al. Compliance of the proximal stomach and dyspeptic symptoms in patients with type I diabetes mellitus. Dig Dis Sci 1995;40:2037-42
   PubMed Web of Science ®Google Scholar
• Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA 2013;310:2640-9
   PubMed Web of Science ®Google Scholar
• Locke GR, Bouras EP, Howden CW, et al. The functional dyspepsia treatment trial (FDTT) key results. Gastroenterology 2013;144(Suppl 1):S140
   Google Scholar
• Van Oudenhove L, Kindt S, Vos R, et al. Influence of buspirone on gastric sensorimotor function in man. Aliment Pharmacol Ther 2008;28:1326-33
   PubMed Web of Science ®Google Scholar
• Tack J, Janssen P, Mosaoka T. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012;11(10):1239-45
   Google Scholar
• Miwa H, Nagahara A, Tominaga K, et al. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol 2009;104(11):2779-87
   PubMed Web of Science ®Google Scholar
• Yin J, Song J, Lei Y, et al. Prokinetic effects of mirtazapine on gastrointestinal transit. Am J Physiol Gastrointest Liver Physiol 2014;306(9):G796-801
   PubMed Web of Science ®Google Scholar
• Gooden JY, Takahashi P. Mirtazapine treatment of diabetic gastroparesis as a novel method to reduce tube-feed residual:a case report. J Med Case Rep 2013;7:38
   PubMedGoogle Scholar
• Johnstone M, Buddhdev P, Peter M, et al. Mirtazapine: A solution for post-operative Gastroparesis? BMJ Case Rep 2009;2009
   Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Mirtazapine for Severe Gastroparesis Unresponsive to Conventional Prokinetic Treatment. Psychosomatics 2006;47(5):440-2
   PubMed Web of Science ®Google Scholar
• Van Oudenhove L, Holvoet L, Bisschops R, et al. A double-blind, randomized, placebo-controlled study of mirtazapine in functional dyspepsia with weight loss. Gastroenterology 2009;136(5):A46-6
   PubMed Web of Science ®Google Scholar
• Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007;26:1251-8
   PubMed Web of Science ®Google Scholar
• Friedenberg FK, Palit A, Parkman HP, et al. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008;103:416-23
   PubMed Web of Science ®Google Scholar
• Yin J, Abell TD, McCallum RW, et al. Gastric neuromodulation with Enterra system for nausea and vomiting in patients with gastroparesis. Neuromodulation 2012;15(3):224-31
   PubMed Web of Science ®Google Scholar
• Grover M, Farrugia G, Lurken M, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 2011;140:1575-85
   PubMed Web of Science ®Google Scholar
• Grover M, Bernard CE, Pasricha PJ, et al. Clinical-histological associations in gastroparesis: results from the gastroparesis clinical research consortium. Neurogastroenterol Motil 2012;24:531-e249
   PubMed Web of Science ®Google Scholar
• Choi KM, Gibbons SJ, Nguyen TV, et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 2008;135:2055-64
   PubMed Web of Science ®Google Scholar
• Hirst G, Edwards F. Role of interstitial cells of cajal in the control of gastric motility. J Pharmacol Sci 2004;96:1-10
   PubMed Web of Science ®Google Scholar
• Horvath V, Vittal H, Lorincz A. Reduced stem cell factor links smooth myoptathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology 2006;130:759-70
   PubMed Web of Science ®Google Scholar
• Neshetian L, Gibbons SJ, Farrugia G. Macrophages in diabetic gastroparesis—the missing link? Neurogastroenterol Motil 2015;27(1):7-18
   PubMed Web of Science ®Google Scholar
• Kashyap PC, Choi KM, Dutta N, et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G1013-19
   PubMed Web of Science ®Google Scholar
• Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discov 2010;9:728-43
   PubMed Web of Science ®Google Scholar
• Mazzone A, Bernard C, Strege P, et al. Altered expression of Ano1 variants in human diabetic gastroparesis. J Biol Chem 2011;286:13393-403
   PubMed Web of Science ®Google Scholar
• Takahashi T. Pathophysiological significance of neuronal nitric oxide synthase in the gastrointestinal tract. J Gastroenterol 2003;38:421-30
   PubMed Web of Science ®Google Scholar
• Gangula P, Mukhopadhyay S, Ravella K, et al. Tetrahydrobiopterin (BH4), a cofactor for nNOS, restores gastric empyting and nNOS expression in female diabetic rats. Am J Physiol Gastrointest Liver Physiol 2010;298:G692-9
   PubMed Web of Science ®Google Scholar
• Gangula P, Mukhopadhyay S, Pasricha PJ, et al. Sepiapterin reverses the changes in gastric nNOS dimerization and function in diabetic gastroparesis. Neurogastroenterol Motil 2010;22:1325-e352
   PubMed Web of Science ®Google Scholar
• Nguyen L, Pasricha PJ. Sapropterin improves gastric accommodation and symptoms in women with diabetic gastroparesis. Neurogastroenterol Motil 2013;25:36
   Web of Science ®Google Scholar